BioStock: Successful new share issue provides tailwinds for Elicera Therapeutics

Pharmaceutical development company Elicera, which targets oncolytic viruses and CAR T-cells, celebrated its first day as a listed company on Nasdaq First North Growth Market on Friday. In connection with this, the company also issued new shares that were subscribed for approximately 171 per cent, which, including the over-allotment, results in a capital injection of 62 MSEK.   

Read the full article at biostock.se:

https://www.biostock.se/en/successful-new-share-issue-provides-tailwinds-for-elicera-therapeutics/

This is a press release from BioStock - Connecting Innovation & Capital.https://www.biostock.se